| ABBV |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$3.68 vs. cons $3.66 |
MEDIUM |
| ABBV |
Report |
Total Net Revenue (Q2 2026) |
BEAT |
pred ~$17.0B vs. cons $16.81B |
MEDIUM |
| ABBV |
Report |
Skyrizi Q2 2026 Revenue |
BEAT |
pred ~$5.0B vs. cons $4.85B |
HIGH |
| ABBV |
Guide |
FY2026 Adjusted EPS Guidance |
BETTER |
guide ~$14.15-14.25 vs. cons $14.18 (FY2026) |
MEDIUM |
| ABBV |
Guide |
FY2026 Net Revenue Guidance |
BETTER |
guide ~$67.5B vs. cons $67.3B (FY2026) |
MEDIUM |
| ABBV |
Guide |
FY2026 Skyrizi/Rinvoq combined sales guidance |
BETTER |
guide ~$32.2B (Skyrizi ~$21.9B + Rinvoq ~$10.3B) vs. cons ~$31.6B (FY2026) |
MEDIUM |
| ABBV |
Guide |
Q3 2026 EPS Guidance (initial print) |
UNKNOWN |
guide ~$3.70 vs. cons $3.68 (Q3 2026, pending IPR&D charges) |
LOW |
| ABBV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.0% |
— |
MEDIUM |
| ABBV |
Return |
5-day cumulative residual |
+0.3% (FADE) |
Underlying beat-and-raise in immunology (Skyrizi/Rinvoq) likely drives an initial positive pop, but with the stock already up ~28% into the print and near/above sell-side targets, the reduced $3.57-3.61 guide optics and repeated IPR&D/milestone charges (Apogee dilutive to 2032) give analysts room to trim near-term EPS even while nudging long-term Skyrizi/Rinvoq estimates higher — a mixed revisions picture that tends to fade an initial pop as profit-taking sets in over the following days rather than sustain follow-through. |
LOW |